ClinicalTrials.gg
CompletedNCT04826172Updated Apr 23, 2024

Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

A Phase 2 interventional study of IMB-1018972 and Placebo in Ischemia and Coronary Artery Disease, sponsored by Imbria Pharmaceuticals, Inc.. Completed at 3 sites in 3 countries. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-23.

Sponsored by Imbria Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Ischemia with a site in Denmark — 4 open to participants now, 5 under way, 1 of them phase 3. Ischemia · Denmark.

Enrollment
12th of 16
58 · median 67
Started
2021
with 1 other
Phase 2
Only one
of the 21
Registered
15th of 21
by date

Among the 21 studies in Ischemia with a site in Denmark, this one is the 12th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2021, is the only one in phase 2, and was the 15th registered.

Ischemia

545 studies on the registry are indexed under Ischemia; 72 are open to participants now.

Browse Ischemia studies →

Open to participants now

4 of the 21 studies in Ischemia with a site in Denmark are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 45 Ischemia studies recruiting now, 35 (78%) set no upper age limit and 5 (11%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 35 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Ischemia with a site in Denmark, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of IMB-1018972 in subjects with obstructive CAD and inducible ischemia.

03

Conditions studied

  • Ischemia
  • Coronary Artery Disease
04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented history of stable angina (CCS grading I-III) or anginal equivalent for ≥1 month prior to screening
  • Ability to safely abstain from beta blockers for 48 hours prior to echo examinations in the opinion of the Investigator
  • Preserved LV systolic function, defined as ≥50% by any imaging modality
  • Obstructive CAD and recent evidence of stress-induced myocardial ischemia

Exclusion criteria

Exclusion Criteria:

  • Women of or who are currently pregnant or breast-feeding
  • Clinically indicated for coronary revascularization (PCI/CABG) at time of screening or LMS or proximal LAD stenosis likely to warrant revascularization during the study period in the opinion of the investigator.
  • Type 1 insulin dependent diabetes mellitus (IDDM)
  • Presence of pacemaker, cardiac resynchronization therapy and/or implantable cardioverter defibrillator
  • Severe or clinically significant valvular heart disease
  • Clinically significant concurrent condition which could prevent the patient from performing any of the protocol-specified assessments, represent a safety concern if the patient participates in the trial or could confound trial assessments of safety or tolerability
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    IMB-1018972 200mg

    Drug: IMB-1018972

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Modified release (MR) oral tablet

  • DrugPlacebo

    Matching oral tablet

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of IMB-1018972 as measured by incidence and severity of treatment emergent AEs (including AEs leading to study drug discontinuation and AEs leading to death), as well as incidence of treatment emergent SAEs

    Time frame: Randomization through Week 10 Safety Follow-up

Secondary outcomes

  1. Change in number of ischemic segments during hyperemia (ischemia defined as absolute MBF ≤2.0 ml/kg/min) as measured by adenosine stress 15O-H2O PET

    Ischemia score defined on the basis of absolute hyperemic MBF as: (1) MBF 2.0-2.3 ml/g/min; (2) 1.7- 2.0 ml/g/min; (3) MBF \<1.7 ml/g/min

    Time frame: Baseline through Week 8

  2. Change in total ischemia burden measured as ischemia score summed across all segments as measured by adenosine stress 15O-H2O PET

    Time frame: Baseline through Week 8

  3. Change in inducible perfusion defect expressed as % of myocardium as measured by adenosine stress 15O-H2O PET

    Time frame: Baseline through Week 8

07

Study locations

3 sites
  • Imbria Investigational Site
    Aarhus, Denmark
  • Imbria Investigational Site
    Turku, Finland
  • Imbria Investigational Site
    Uppsala, Sweden
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Sep 2023, 28 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2021
First posted
Apr 1, 2021
StartActual
Apr 23, 2021
Primary completionActual
Sep 21, 2023
CompletionActual
Sep 21, 2023
Last update
Apr 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04826172
Lead sponsor
Imbria Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Apr 1, 2021
Start date
Apr 23, 2021
Primary completion
Sep 21, 2023
Completion
Sep 21, 2023
Last update
Apr 23, 2024

Study contacts

Medical Monitor, MD
study chair · Imbria Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ninerafaxstat

Start the discussion